Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06140524 · ClinicalTrials.gov registry record · Phase 2
A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma
A Phase 2 study of Monoclonal Gammopathy of Undetermined Significance (MGUS) and Smoldering Multiple Myeloma (SMM), sponsored by Regeneron Pharmaceuticals.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 116
- Enrollment target
- 13
- Study locations
NCT06140524 is a Phase 2 study of Monoclonal Gammopathy of Undetermined Significance (MGUS) and Smoldering Multiple Myeloma (SMM) that is actively recruiting participants, run by Regeneron Pharmaceuticals. The registered enrollment target is 116 participants. The trial reports 13 study locations across 11 states.
The verdict
NCT06140524, a Phase 2 study of Monoclonal Gammopathy of Undetermined Significance (MGUS) and Smoldering Multiple Myeloma (SMM), is actively recruiting participants, sponsored by Regeneron Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 116 participants
- Enrollment target
- 13
- Study locations
Study Summary
This study is researching an investigational drug called linvoseltamab ("study drug") in participants at moderate risk of developing multiple myeloma (about 3 to 10% average annual risk), a group that consists of patients with precancerous conditions called High-Risk Monoclonal Gammopathy of Undetermined Significance (HR-MGUS) and Non-High-Risk Smoldering Multiple Myeloma (NHR-SMM). The primary purpose of the study is to understand how well the study drug can eliminate abnormal plasma cells and laboratory signs of HR-MGUS and NHR-SMM. The study is looking at several other research questions, including: * How many participants treated with linvoseltamab have improvement of their HR-MGUS or NHR-SMM? * What side effects may happen from taking the study drug? * How much study drug is in the blood at different times? * Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects).
Conditions Studied
Interventions
- DRUG Linvoseltamab
Study Locations (13)
Other
- Hospital Sant Pau - Barcelona
- Universitaru Hospital La Princesa - Madrid
- Hospital General Universitario Morales Meseguer - Murcia
Maryland
- Johns Hopkins Hospital - Baltimore
Massachusetts
- Dana-Farber Cancer Institute - Boston
Michigan
- University of Michigan Health - Ann Arbor
New York
- Stony Brook University Hospital - Stony Brook
Pennsylvania
- Thomas Jefferson University Hospital - Philadelphia
Washington
- University of Washington - Seattle
Andalusia
- Hospital Universitario Virgen de las Nieves - Granada
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 116 participants |
| Start Date | 2024-09-16 |
| Est. Completion | 2032-05-18 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06140524
The ClinicalTrials.gov registry entry for NCT06140524 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 116 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Regeneron Pharmaceuticals, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Monoclonal Gammopathy of Undetermined Significance (MGUS) appearing as the primary indexed condition, and to 1 intervention - of which Linvoseltamab is the first listed.
NCT06140524 reports 13 study locations spanning 11 distinct geographic areas - top geographies include Other, Maryland, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06140524 about?
NCT06140524 is a clinical study titled "A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma". This study is researching an investigational drug called linvoseltamab ("study drug") in participants at moderate risk of developing multiple myeloma (about 3 to 10% average annual risk), a group that consists of patients with precancerous conditions called High-Risk Monoclonal Gammopathy of Undeter...
What is the current status of trial NCT06140524?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 116 participants. The study started on 2024-09-16. Estimated completion is 2032-05-18.
What conditions does trial NCT06140524 study?
This clinical trial studies the following conditions: Monoclonal Gammopathy of Undetermined Significance (MGUS), Smoldering Multiple Myeloma (SMM).
What interventions are being tested in trial NCT06140524?
The interventions under investigation include: Linvoseltamab (DRUG).
Who is sponsoring clinical trial NCT06140524?
This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06140524 being conducted?
This trial has 13 study locations across Maryland, Massachusetts, Michigan, New York, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Monoclonal Gammopathy of Undetermined Significance (MGUS)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Monoclonal Gammopathy of Undetermined Significance (MGUS)
All registered trials for this condition
Smoldering Multiple Myeloma (SMM)
All registered trials for this condition
Maryland
All trials with a study site in Maryland
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.